Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.80 |
| ▸ | CDK4 | P11802 | 11/20 | 0.80 |
| ▸ | EIF2AK2 | P19525 | 5/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614634 | 0.89 | CDK2 (1.00) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4613772 | 0.87 | CDK2 (0.77) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4615045 | 0.81 | CDK2 (0.68) | CDK2CDK4EIF2AK2 | |
| SCHEMBL4613380 | 0.78 | CDK2 (0.76) | CDK2CDK4EIF2AK2ABL1PRKCA | |
| SCHEMBL4614974 | 0.77 | CDK2 (0.75) | CDK2CDK4EIF2AK2ABL1PRKCA | |
| SCHEMBL13239592 | 0.75 | EIF2AK2 (0.67) | CDK2CDK4EIF2AK2ABL1PRKCA | |
| SCHEMBL4613817 | 0.74 | CDK2 (1.00) | CDK2CDK4ABL1PRKCABCR | |
| SCHEMBL8316804 | 0.74 | CDK4 (0.59) | CDK2CDK4EIF2AK2 | |
| SCHEMBL8316906 | 0.73 | CDK4 (0.58) | CDK2CDK4EIF2AK2 | |
| SCHEMBL8320692 | 0.72 | CDK2 (0.57) | CDK2CDK4EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132746-A1 | Inhibitors of cyclin dependent kinases as anti-cancer agent | CDK2, CCNK, CDK3 | CDK2 1/4885CDK4 5/4885EIF2AK2 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.